Estradiol at physiological concentrations intervenes in apoptotic death cascades and ameliorates neuronal death in experimental models of focal and global ischemia. The cellular targets that mediate estradiol protection of hippocampal neurons in global ischemia are, however, unclear. The present study examined the hypothesis that estradiol protects hippocampal neurons in ovariectomized rats via estrogen receptor (ER)␣ and/or ␤. T HE BENEFITS OF postmenopausal estrogen replacement therapy for protecting the brain against the neuronal death associated with neurological diseases and disorders remain controversial. Global ischemia, arising during cardiac arrest or surgery in humans or induced experimentally in animals, elicits selective, delayed neuronal death; pyramidal neurons of the hippocampal CA1 are particularly vulnerable (1, 2). The ischemia-induced loss of CA1 neurons is associated with cognitive deficits. 17␤-Estradiol (E 2 ), the primary estrogen produced and secreted by the ovaries, and other estrogens afford neuroprotection in experimental models of global and focal ischemia (3-9). Recent work from this laboratory demonstrates that E 2 at levels considered physiological for postmenopausal women prevents the activation of apoptotic signaling cascades and ameliorates global ischemia-induced neuronal loss in male gerbils (7). However, the cellular targets that mediate the protective actions of E 2 on hippocampal neurons are, as yet, unclear.
T HE BENEFITS OF postmenopausal estrogen replacement therapy for protecting the brain against the neuronal death associated with neurological diseases and disorders remain controversial. Global ischemia, arising during cardiac arrest or surgery in humans or induced experimentally in animals, elicits selective, delayed neuronal death; pyramidal neurons of the hippocampal CA1 are particularly vulnerable (1, 2) . The ischemia-induced loss of CA1 neurons is associated with cognitive deficits. 17␤-Estradiol (E 2 ), the primary estrogen produced and secreted by the ovaries, and other estrogens afford neuroprotection in experimental models of global and focal ischemia (3) (4) (5) (6) (7) (8) (9) . Recent work from this laboratory demonstrates that E 2 at levels considered physiological for postmenopausal women prevents the activation of apoptotic signaling cascades and ameliorates global ischemia-induced neuronal loss in male gerbils (7) . However, the cellular targets that mediate the protective actions of E 2 on hippocampal neurons are, as yet, unclear.
Estrogen exerts a number of physiological actions via interaction with intracellular estrogen receptors (ERs), which serve as ligand-activated transcription factors (reviewed in Refs. 3, 6, 10, and 11) . Both of the known ER subtypes, ER␣ and ER␤, are expressed in hippocampal neurons (12) (13) (14) (15) . E 2 has widespread actions on the brain. In the hippocampus, E 2 regulates spine density (16, 17) , synapse number (18) , the synthesis of neurotrophic factors (3, 6, 19) , and N-methyld-aspartate receptor expression (18, 20) . Studies involving mice with targeted deletions of ER␣ and ER␤ indicate that ER␣ mediates E 2 protection of cortical neurons in an animal model of focal ischemia (21) . However, ER␤ is implicated in the neuroprotective actions of E 2 in mice subjected to global ischemia (22) , and agonists selective for both ER␣ and ER␤ can partially protect gerbil CA1 neurons from global ischemia-induced cell death (9) .
The purpose of the present study was: 1) to determine whether the neuroprotective effects of E 2 in a global ischemia model, which produces selective, delayed death of CA1 pyramidal neurons in rats, is mediated by ERs; 2) to identify which ER mediates neuroprotection in this model; and 3) to determine the ability of E 2 and neuronal injury (global ischemia) to regulate expression of ER␣ and ER␤ in the hippocampal CA1. We show that the broad-spectrum ER antagonist ICI 182,780 abolishes the neuroprotective effects of E 2 in ovariohysterectomized (ovx) female rats subjected to global ischemia. To validate the dose of the ER␣-selective agonist propyl pyrazole triol (PPT) in eliciting ER␣-mediated neuroendocrine responses and the specificity of the ER␤ WAY 200070 -3, we performed independent physiological tests. At the doses chosen for the ischemia studies, PPT, but not WAY 200070 -3, facilitated female reproductive behavior, suppressed LH release, and minimized body weight gain.
Both the ER␣ and ER␤ agonists afforded protection against global ischemia-induced loss of hippocampal CA1 neurons in approximately 50% of animals. Estrogen pretreatment and global ischemia increased ER␣, but not ER␤, protein expression in the CA1. These findings indicate that ERs mediate the survival of CA1 neurons afforded by E 2 in global ischemia and suggest a role for both ER␣ and ER␤ in protection against global ischemia-induced cell death.
Materials and Methods

Animals and experimental treatments
All procedures were performed in accordance with the National Institutes of Health (NIH) Guidelines for the Care and Use of Laboratory Animals and were approved by the Albert Einstein College of Medicine Institutional Animal Care and Use Committee. Rodents were maintained in a temperature-and light-controlled environment with 14-h light, 10-h dark cycle and had access to standard rat chow and water ad libitum.
Ovariohysterectomy and E 2 pellet placement
Twenty-one-day-old female Sprague Dawley rats (Charles River Laboratories, Inc., Wilmington, MA) were ovx on day zero, under halothane (3% for induction, 1% for maintenance) anesthesia. On the same day, pellets containing E 2 (50 g; 21-d sustained release; Innovative Research of America, Sarasota, FL) or placebo were inserted sc beneath the dorsal surface of the neck. These pellets are designed to maintain serum hormone levels for 21 d. Experiments were carried out so that animals weighed approximately 100 -120 g at the time global ischemia was induced, because the four-vessel occlusion (see below) produces the most reliable ischemia in rats of this size.
ER-selective agonists and ER antagonist compounds
For experiments using ER-selective compounds, ovx rats received daily sc injections of: 1) the ER␣ agonist PPT (provided by Dr. Istvan Merchenthaler, Wyeth-Ayerst Laboratories, Inc., Collegeville, PA) at a dose of 10 mg/kg; 2) an ER␤ agonist WAY 200070 -3 (provided by Dr. Heather Harris, Wyeth-Ayerst Laboratories, Inc.) at a dose of 1 mg/kg; or 3) vehicle, 25% dimethylsulfoxide in 0.9% saline, for a total vol of 200 l. Agonists were always injected between 0700 and 0800 h. On the day of ischemia induction, the injections occurred between 2 and 4 h before surgery. For intracerebroventricular (ICV) injections: 1) 100 g of the nonselective ER antagonist ICI 182,780 (Tocris Cookson, Inc., Ellisville, MO), or 2) vehicle (50% dimethylsulfoxide, in 0.9% saline) was injected into the right lateral ventricle, in a vol of 5 l per injection, with a Hamilton syringe (Fisher Scientific, Pittsburgh, PA) using standard stereotaxic methods. The structures of these compounds are shown in Fig. 1 .
ER-selective agonist treatment
For experiments using ER-selective agonists, PPT (ER␣ agonist), WAY 200070 -3 (ER␤ agonist), or vehicle was administered once daily from 24 h after ovx until d 21, when rodents were euthanized for histology. Body weights were measured at the time of ovx and then every 2-3 d to determine the correct dosage of the ER-selective agonists and to assess ER agonist effects on weight gain. PPT is 410-fold selective for ER␣ relative to ER␤ (23) . WAY 200070 -3 is 110-fold selective for ER␤, relative to ER␣, as assessed by radioligand binding assays, and it fails to stimulate uterine weight gain when administered sc at doses as high as 50 mg/kg (H. Harris, personal communication). Although the ability of WAY 200070 -3 to cross the blood-brain barrier is not well characterized, upon sc administration of 3 mg/kg WAY 200070 -3, a concentration of 12 ng/g brain tissue is achieved by 1 h (H. Harris, personal communication).
Global ischemia
On d 13, using halothane anesthesia, the vertebral arteries were exposed through a midline occipital-suboccipital incision and coagulated with bipolar cauterization between the first and second cervical vertebral bodies. This procedure by itself has no effect on cerebral blood flow but prevents collateral circulation to the forebrain during transient carotid artery occlusion on d 14. Twenty-four hours later, transient global ischemia was accomplished by bilateral occlusion of the common carotid arteries for 10 min followed by reperfusion. A rectal probe was inserted to monitor core temperature and was maintained at 36.5-37.5 C using a heat lamp during ischemia. Sham-operated rats had their vertebral arteries coagulated on d 13.
ICV injections
In the first experiment, immediately after ischemia (24 h after coagulating the vertebral arteries for sham-treated rats) and again 12 h later, rats were positioned in a stereotaxic apparatus and ICV injections performed under halothane anesthesia. The position of the right lateral ventricle was calculated based on the position of bregma (anterior/ posterior, 0.92 mm; medial/lateral, 1.2 mm; dorsal/ventral, 3.6 mm), and then the nonselective ER antagonist ICI 182,780 or vehicle was infused with a 28-gauge needle, in a vol of 5 l per infusion, over 1 min. The injection needle was left in place for an additional 1 min before being withdrawn.
Histological analysis
We first examined the impact of transient global ischemia on the volume of the hippocampal CA1. Rats were subjected to global ischemia or sham operation (n ϭ 6 per group) and, at 7 d after surgery, were killed by transcardiac perfusion with 4% paraformaldehyde under deep anesthesia. Brains were rapidly removed, and the volume of the CA1 from ischemic and sham rats was assessed by stereological methods. Toluidine blue-stained coronal sections (20 m) were collected through the entire dorsal hippocampus (bregma Ϫ2.3 to Ϫ4.5 mm). Digital images of every tenth section from each animal (ϳ100 sections per brain) were captured and used to trace the outline of the CA1. The mean area Ϯ sem of the entire CA1 was calculated and multiplied by the section thickness times the number of sections along the rostral/caudal axis. Although the CA1 pyramidal neurons were nearly ablated at 7 d after ischemia, no statistically significant difference in volume of the CA1 was detected for ischemic (2.43 Ϯ 0.6 ϫ 10 8 m 3 ; n ϭ 6) vs. sham-operated rats (2.42 Ϯ 0.5 ϫ 10 8 m 3 ; n ϭ 6). Based on this information, counts of pyramidal neurons were assessed in a 250-m length of the CA1 pyramidal cell layer, in 3-4 sections per animal, at 7 d after ischemia or sham operation as described below.
Seven days after global ischemia (d 21 after ovx), animals were euthanized by deep anesthesia, and blood was collected by cardiac puncture for analysis of serum E 2 levels. Each rat was transcardially perfused using 0.9% saline solution with heparin (150 ml; 15 min) followed by ice-cold 10% buffered formalin phosphate (200 ml; 20 min; Fisher Scientific, Pittsburgh, PA). Brains were then removed, placed in formalin at 4 C overnight, fixed in 30% sucrose in PBS at 4 C for 48 h, and then frozen at Ϫ40 C. The dorsal hippocampus was coronally sectioned on a cryotome into 15-m slices, and every fourth section was collected, mounted, and stained with toluidine blue. Using ϫ60 magnification, the CA1 region of the left and right hippocampi was photographed. Surviving pyramidal neurons in a 250-m length of the stratum pyramidale of the left and right CA1 (see arrows in Fig. 2B , panel A) were counted. Cell counts are expressed as the average number of surviving neurons per side, counted from four sections per animal. More than 95% of the cells in the stratum pyramidale are pyramidal neurons; most glia and the cell bodies of inhibitory interneurons are localized to the stratum radiatum or stratum oriens. It is well established that a brief (10 min) episode of global ischemia affords delayed, selective death of CA1 pyramidal neurons. Inhibitory interneurons of the CA1 and all neurons of the nearby CA2 or transition zone, CA3, and dentate gyrus survive (2) .
Behavioral testing
Adult female Sprague Dawley rats, weighing 200 -350 g (Taconic Farms, Inc., Germantown, NY), were ovx and maintained in a reverse light-dark cycle (14-h dark, 10-h light, with lights off at 1100 h). Two weeks later, rats (n ϭ 8) were randomly assigned to receive E 2 benzoate (2 g in 100 l peanut oil) or an ER-selective agonist sc daily for 2 d. The PPT dose was 10 mg/kg⅐d, and the WAY 200070 -3 dose was 1 mg/kg⅐d. On the third day, progesterone (500 g in 100 l peanut oil) was administered, and behavior testing was performed 4 h later. All tests were performed in the dark, under red light illumination, between 1300 and 1700 h. Each female rat was placed into a cage with a sexually active male rat, and female sexual receptivity was recorded. The lordosis quotient (LQ) was determined by counting the number of times the female assumed the lordosis posture, in response to 10 mount attempts by the male, and then multiplied by 100. One week later, the same female rats were injected with a different ER-selective agonist or E 2 benzoate, and behavior testing was repeated. Testing was continued until all female rats were exposed to each treatment.
Serum E 2 assay
Tubes containing whole blood were placed on ice for 20 min and centrifuged at 300 ϫ g for 5 min, and sera were collected and stored (Ϫ20 C) until analyzed. Serum hormone levels were measured by fluoroimmunoassay using the DELPHIA E 2 assay (PerkinElmer Life Sciences, Turku, Finland). All assays were performed in duplicate, and the mean value was reported. The sensitivity of detection was 13 pg/ml. The interand intraassay coefficients of variance were 10.1% and 4.1%, respectively.
LH assay
Serum LH levels were measured by enzyme immunoassay (Biotrak; Amersham Biosciences, Buckinghamshire, UK). Assays were performed in duplicate, and the mean value was reported. The sensitivity of detection is 0.1 ng/ml. The cross-reactivity of LH with rat FSH was less than 0.016%. The inter-and intraassay coefficients of variance are 6.2% and 2.4%, respectively.
Western blot
For quantification of protein in the CA1 hippocampal region, immunoblots were performed as described (7) . The ovx animals received placebo or E 2 pellets as described above and were subjected to sham operation or 10-min global ischemia 2 wk later. Animals were deeply anesthetized and euthanized by decapitation at 24 h and 48 h after ischemia or 24 h after sham operation. Before decapitation, blood samples were collected by cardiac puncture from animals killed 24 h after ischemia or sham operation, for later analysis of serum E 2 levels on d 15. Hippocampi were quickly dissected and cut into 1-mm transverse slices on a McIllwain tissue chopper (Vibratone Co., St. Louis, MO). The entire CA1 region from these slices of the left and right hippocampus was separated quickly by microdissection, placed in ice-cold PBS containing the protease inhibitor phenylmethylsulfonylfluoride (1 mm; SigmaAldrich Corp., St. Louis, MO), and stored at Ϫ20 C until used. Protein concentration of samples was determined using the BCA protein assay kit (Pierce Chemical Co., Rockford, IL). Laemmli's buffer was combined with 30 g protein and loaded onto 10% polyacrylamide minigels (Bio-Rad Laboratories, Inc., Richmond, CA) and then subjected to electrophoresis.
Protein bands were transferred onto a polyvinylidene fluoride membrane (Millipore Corp., Bedford, MA). After blocking for 30 min with 25 mm Tris-HCl (pH 8.0) containing 125 mm NaCl, 0.1% Tween 20, and 4% skim milk, membranes were incubated with primary antibody, washed, and then incubated with secondary antibody. After reaction, membranes were treated with enhanced chemiluminescence reagents (Amersham Biosciences, Arlington Heights, IL) and apposed to x-ray film (Eastman Kodak Co., Rochester, NY).
Antibodies for Western blot
Primary antibodies were: 1) a mouse monoclonal antibody directed to human ER␣ (ER␣ 6F11; Vector Laboratories Ltd., Burlingame, CA) at a concentration of 1:100 and incubated at 4 C overnight, and 2) a polyclonal rabbit antibody directed to amino acids 64 -82 of rat ER␤ (ER␤ antibody; provided by Dr. Stephen Alves, Merck & Co., Inc., Rahway, NJ) at a concentration of 1:30,000 and incubated at room temperature for 16 h. Both of these antibodies have been validated for use in immunoblotting of rat brain tissue. Secondary antibodies were: 1) a horseradish peroxidase-conjugated antimouse IgG for ER␣ (Cell Signaling Technology, Inc., Beverly, MA) at a concentration of 1:1000 and incubated for 2 h at room temperature; and 2) horseradish peroxidase-conjugated antirabbit IgG for ER␤ (Cell Signaling Technology, Inc.) at a concentration of 1:2,000 and incubated for 1.5 h at room temperature.
A Scan Jet 4-C computing densitometer (Hewlett-Packard Co., Palo Alto, CA) was used with NIH Image 1.61 software to quantitate protein abundance. Optical densities of ER bands were first normalized to the amount of protein loaded, assessed by stripping and reblotting for type III ␤-tubulin in each sample. These values were then expressed relative to normalized values obtained for samples from ovx, sham-operated rats on the same membrane to allow for comparison of band densities of immunoblots exposed to different pieces of film.
Statistical analysis
Data analysis was performed using SPSS 12.0 (SPSS, Inc., Chicago, IL). One-way ANOVA was used to compare group means of normally distributed data (serum E 2 , serum LH, rat weight gain, and immunoblots) with Newman-Keuls post hoc analysis. Friedman's test with Dunn's multiple-comparison post hoc analysis was performed to analyze lordosis behavior tests. Kruskal Wallis testing was used for comparing neuron counts after E 2 and/or ICI 182,780 treatment, followed by Dunn's post hoc analysis. Other nonparametric methods were used to analyze pyramidal neuron counts after ER subtype-selective agonist treatment, because the data were bimodal. Subjects were divided into two categories based on the number of surviving neurons. Animals with greater than 40 surviving neurons per 250 m were considered to be protected, and animals with less than 30 surviving neurons per 250 m were considered not to be protected. Then 2 and Fisher's exact test were used to analyze whether there were treatment-related differences in the number of animals protected and not protected and in the median number of surviving neurons. Differences were considered significant at P Յ 0.05.
Results
To examine the cellular targets that mediate the neuroprotective actions of estrogen on hippocampal neurons, we treated rats with E 2 or placebo for 14 d, subjected animals to sham operation or global ischemia, and acutely administered the broad-spectrum ER antagonist ICI 182,780 or vehicle at 0 and 12 h after reperfusion. E 2 and placebo pellets remained in place until rats were killed for histological evaluation 7 d after ischemia. Global ischemia induced a substantial loss of hippocampal CA1 neurons in vehicle-treated rats at 7 d post ischemia (loss of ϳ80% of neurons in the CA1 pyramidal cell layer; Fig. 2A ). Long-term E 2 treatment afforded robust neuroprotection (ϳ50% neuronal survival in the CA1) in nine of nine treated rats. The ER antagonist ICI 182,780 alone (in -FIG. 2 . ER antagonist ICI 182,780 treatment abolishes E 2 neuroprotection after global ischemia. All groups were treated with E 2 or placebo (P) for 2 wk before undergoing ischemia or sham surgery. ICI 182,780 (ICI) or vehicle (V) was then injected ICV immediately after ischemia and repeated 12 h later (for sham groups, ICI 182,780 or vehicle was injected 24 h and 36 h after sham operation). A, E 2 treatment affords robust neuroprotection in the CA1 region of the hippocampus after global ischemia (E 2 ϩV vs. PϩV in ischemic animals; #, P Ͻ 0.002). Injection of the ER antagonist ICI 182,780 after E 2 treatment and ischemia abolished this neuroprotection (E 2 ϩICI vs. E 2 ϩV in ischemic animals: †, P Ͻ 0.002). Treatment with the ER antagonist did not affect the number of surviving neurons in any of the other treatment groups; therefore, for statistical analysis, sham-operated vehicle and ICI 182,780-treated groups were combined. Rats that underwent global ischemia had significantly fewer surviving neurons than the sham-operated groups (*, P Ͻ 0.001). Data (n ϭ 3-10 per treatment group) are represented as medians and analyzed using Kruskal Wallis with Dunn's post hoc analysis. B, Histologic evaluation of the dorsal hippocampus after global ischemia or sham operation in low (ϫ4, top) and high power (ϫ60, bottom) magnification. DG, Dentate gyrus; SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum. Placebo (A and B) and E 2 (C and D)-treated rats that underwent sham operation similarly have many surviving neurons in the CA1 region of the hippocampus. Placebo-treated rats that underwent global ischemia (E and F) have selective, delayed neuronal death in CA1. G and H, E 2 -treated rats that underwent global ischemia have selective, delayed neuronal death in CA1, but approximately 50% of the neurons survived. I and J, E 2 -treated rats that underwent global ischemia and then received ICI 182,780 have few surviving neurons in the CA1 region. C, Rats treated with E 2 have higher serum E 2 levels than the placebo (P)-treated group. Sera were collected 15 d (E 2 15d) or 21 d (E 2 21d) after E 2 pellets were placed. Statistically significant differences between hormonal treatments and time are shown (E 2 15d vs. P: *, P Ͻ 0.001; E 2 21d vs. P: †, P Ͻ 0.002; E 2 15d vs. E 2 21d: *, P Ͻ 0.001). Data (n ϭ 20 -33 per treatment group) are represented as mean Ϯ SE and analyzed using one-way ANOVA.
jected at 0 and 12 h after reperfusion) did not detectably alter the number of surviving neurons in sham-operated or ischemic rats ( Fig. 2A) but abrogated E 2 -elicited neuroprotection (Fig. 2B ). These findings indicate that E 2 acts via the classical ERs to elicit protection of hippocampal neurons.
To confirm that estrogen pellet implantation effectively released E 2 , we monitored serum E 2 levels. Groups treated with E 2 exhibited significantly higher serum E 2 levels than did placebo-treated rats, evident at 15 and 21 d after pellet implantation (Fig. 2C) . The mean serum E 2 level on d 15 (64 Ϯ 7.0 pg/ml), measured in animals killed 24 h after ischemia for the ER immunoblotting study (see below), was slightly above the peak physiological level seen during proestrus. By d 21, the mean serum E 2 level (33 Ϯ 2.9 pg/ml) was in the midphysiological range. The change between d 15 and d 21 most likely reflects the increasing body weight of the animals (see Fig. 3B ) and may also indicate that, by the end of the experiment, the 21-d pellets have released most of their E 2 .
To evaluate the potential roles of ER␣ vs. ER␤ in mediating estrogen protection of hippocampal neurons, we administered ER␣-and ER␤-selective agonists to ovx rats for 14 d before and 7 d after ischemia. To validate the doses of the agonists used for protection, and to evaluate the specificity of the agonists for the ER subtypes, we tested known actions of estrogen mediated entirely (lordosis behavior) or at least in part (suppression of LH release and weight gain) at the level of the brain. In a pilot study, the ER␣ agonist PPT at 2 mg/kg⅐d did not elicit a lordosis response; rats exhibited a median LQ of zero (interquartile range: 0, 15; n ϭ 8). PPT at a higher dose (10 mg/kg) elicited a high median LQ similar to that produced by administration of E 2 benzoate (Fig. 3A) . This finding verifies that PPT at 10 mg/kg crosses the bloodbrain barrier and achieves a concentration in brain tissue sufficient to produce neuroendocrine responses mediated by ER␣ at the level of the hypothalamus within 1-2 d after administration. The ER␤-selective agonist WAY 200070 -3 did not elicit lordosis at either 1 mg/kg (Fig. 3A) or 10 mg/kg (median LQ ϭ 10, interquartile range: 5, 15; n ϭ 8), suggesting that it does not cross-react detectably with ER␣ to elicit sexual behavior in this dose range.
The ER␣-selective agonist PPT at 10 mg/kg⅐d, but not WAY 200070 -3 (1 mg/kg⅐d), also reduced weight gain by young rats during the 3-wk regimen used in the ischemia studies (Fig. 3B) . Control (vehicle-treated) rats gained an average of 92 g during the 21 d, whereas PPT-treated rats (10 mg/kg⅐d) gained an average of only 59 g. These PPT-treated rats differed significantly from both the vehicle-and WAY 200070 -3-treated groups (P Ͻ 0.01). Rats treated with 2 mg/ kg⅐d PPT also gained significantly more weight than did those treated with 10 mg/kg PPT (P Ͻ 0.002). The weight gained by rats treated with the lower ER␣ agonist dose (data not illustrated) did not differ significantly from either that of the vehicle-or of the ER␤-agonist-treated groups. Within a given agonist treatment group, there was no significant difference in weight gain for ischemic vs. sham-operated rats.
Estrogen also elicits negative feedback inhibition of LH release, at least in part via ER␣ (24) . Administration of the ER␣-selective agonist PPT (2 mg/kg⅐d) reduced the median LH serum level in ovx rats from approximately 15 ng/ml to 4.6 ng/ml (interquartile range: 2.4, 9.0; P Ͻ 0.02 vs. vehicletreated rats), consistent with negative feedback inhibition of LH release. Increasing the dose of the ER␣ agonist to 10 mg/kg⅐d reduced the mean serum LH level further (Fig. 3C) . In contrast, WAY 200070 -3 did not detectably alter serum LH levels relative to ovx, vehicle-treated females (Fig. 3C) .
Both the ER␣-(10 mg/kg⅐d) and ER␤-(1 mg/kg⅐d) selective agonists elicited pronounced neuroprotection in approximately 40 -50% of treated ischemic rats. Both groups exhibited bimodal distributions in the number of surviving neurons in the hippocampal CA1. Approximately 40 -50% of
FIG. 3. ER-selective agonist treatment and physiologic responses. A,
Treatment with the ER␣-selective agonist PPT induces lordosis behavior. Two weeks after ovx, the ER␣ agonist (PPT), the ER␤ agonist (WAY), or E 2 benzoate (E 2 ) was administered for two sequential days. Progesterone was given on the third day, and behavioral testing was performed 4 h later. WAY vs. E 2 : *, P Ͻ 0.001; WAY vs. PPT: †, P Ͻ 0.05. Data are expressed as medians (n ϭ 8) and analyzed using Friedman test. B, Treatment with the ER␣-selective agonist PPT reduces rat weight gain. Total weight gain determined after 21 d of daily ER agonist or vehicle treatment. PPT vs. V or WAY: *, P Ͻ 0.001. Data (n ϭ 17-19 per treatment group) are expressed as mean Ϯ SE and analyzed using ANOVA. C, ER␣ agonist treatment causes feedback inhibition of LH. Sera were collected after 21 d of daily hormone administration. PPT vs. V: †, P Ͻ 0.02; PPT vs. WAY: *, P Ͻ 0.001). Data (n ϭ 16 -19 per treatment group) are expressed as mean Ϯ SE and analyzed using ANOVA.
the rats treated with each agonist showed virtually complete survival of CA1 pyramidal neurons; the remainder of the rats exhibited approximately10% surviving neurons, a result statistically indistinguishable from that of the vehicle-treated ischemia group (Fig. 4) . The behaviorally ineffective dose of PPT, 2 mg/kg, elicited modest protection in only two of seven rats subjected to global ischemia (data not shown). Interestingly, these two rats gained less weight during the experiment (43.5 Ϯ 9.1 g) than did the four rats that showed extensive loss of CA1 pyramidal neurons (83.6 Ϯ 11.3 g). Raising the dose of WAY 200070 -3 to 10 mg/kg did not significantly improve the outcome relative to that of the lower dose (one of five rats showed increased survival of CA1 neurons relative to vehicle controls). Neither ER agonist induced detectable pyramidal cell loss in CA1 when given alone to sham-operated rats.
To assess whether the bimodal distribution of CA1 pyramidal neuron survival was related to individual differences in accessibility of brain tissues to 10 mg/kg PPT, we examined serum LH levels in protected (n ϭ 5) and nonprotected (n ϭ 8) rats. Mean LH levels were essentially identical in the two groups (protected, 2.35 Ϯ 0.8 ng/ml vs. nonprotected, 2.25 Ϯ 0.8 ng/ml). Likewise, there was no significant difference between LH levels and pyramidal cell survival in the CA1 of rats treated with 1 mg/kg WAY 200070 -3 (protected, 27.0 Ϯ 15.6 ng/ml, n ϭ 5; nonprotected, 19.4 Ϯ 7.2 ng/ml, n ϭ 6). We also detected no difference in weight gain during the 3 wk of agonist administration in PPT-treated females that were protected (47.8 Ϯ 14.6 g) and not protected (57. Previous studies indicate that neuronal injury, including focal ischemia, can modify ER expression levels (25, 26) . Therefore, we determined the abundance of ER␣ and ER␤ protein in the CA1 region of the hippocampus of ovx rats treated with placebo or E 2 pellets for 14 d before global ischemia or sham operation. Global ischemia induced a significant increase in ER␣ protein expression, evident at 24 and 48 h after ischemia in the placebo-treated groups relative to placebo-treated, sham-operated rats (Fig. 5 ). E 2 pretreatment alone also increased ER␣ protein levels in CA1 in shamoperated rats. The combination of E 2 pretreatment and ischemia did not increase ER␣ protein levels above that produced by either manipulation alone. Immunoblots for ER␣ in other hippocampal subfields indicated that neither ischemia nor estrogen changed ER␣ levels in the dentate gyrus (data not illustrated). In CA3, ischemia, but not estrogen, modestly increased ER␣ at both 24 and 48 h. Estrogen prevented the ischemia-induced increase at 24 h but not 48 h (data not illustrated). Although global ischemia induced a trend toward down-regulation of ER␤ protein in CA1, this effect was not significant at either time ( Fig. 6 ; ANOVA, P Ͻ 0.06). Likewise, E 2 pretreatment did not significantly alter ER␤ WAYϩsham: **, P Ͻ 0.02). Differences in the number of rats per group with more than 40 surviving neurons after drug treatment and ischemia were analyzed using 2 (ER␤ϩischemia vs. Vϩischemia: †, P ϭ 0.04; ER␣ϩischemia vs. Vϩischemia: #, P ϭ 0.05).
FIG. 5. ER␣ protein expression in ovx rats is up-regulated in CA1 by E 2 and after global ischemia. Rats were treated with E 2 pellets or placebo (P) for 2 wk before undergoing global ischemia or sham surgery. Rats were euthanized 24 h (24) or 48 h (48) after ischemia (I) or 0 h for sham operation (S). A, Representative immunoblots of ER␣ (top) and ␤-tubulin (bottom) in hippocampal CA1 from rats treated under each experimental condition. B, Quantitative analysis of ER␣ after ischemia. ER␣ is up-regulated at 24 h and 48 h after global ischemia in placebo-treated groups (Pϩ24 and Pϩ48 vs. C: **, P Ͻ 0.001). ER␣ is also up-regulated in all E 2 -treated groups (E 2 ϩ24 and E 2 ϩS vs. S: *, P Ͻ 0.01; E 2 ϩ48 vs. C: **, P Ͻ 0.001). For each treatment, ER␣ antibody is normalized to ␤-tubulin and expressed as the fold stimulation over that of placebo-treated, sham-operated rats. Values represent mean Ϯ SEM (n ϭ 6) analyzed using ANOVA.
protein abundance in the CA1 of either ischemic females or sham-operated rats.
Discussion
The ability of estrogen to afford protection in animal models of focal and global ischemia is well established (3-9). Our demonstration that E 2 affords robust protection in estrogendeprived female rats is consistent with findings of others, i.e. that estrogen affords protection against global ischemia-induced neuronal death in proestrous female rats (5) and in male and female gerbils (7, 8, (27) (28) (29) and mice (30). Our study extends those findings in that it identifies cellular targets that mediate the protective actions of E 2 on rat hippocampal neurons in vivo. We demonstrate that the broad-spectrum ER antagonist ICI 182,780 (given ICV at 0 and 12 h after ischemia) abolished E 2 protection, arguing against a role for ER-independent mechanisms in estrogen protection in this model. Because the ER antagonist was infused directly into the brain ventricular system, this finding also implicates brain ERs as the mediators of estrogen neuroprotection in transient global ischemia. These data extend previous work in female gerbils showing that systemic administration of the selective estrogen response modifiers, raloxifene and tamoxifen, can attenuate estrogen's protective actions on global ischemia-induced cell death in CA1 neurons (8, 9) .
We also report the novel finding that pretreatment with agonists selective for both ER␣ and ER␤ can preserve a large majority of hippocampal CA1 pyramidal neurons from global ischemia-induced death in some rats. The ER␣-selective agonist PPT and the ER␤-selective agonist WAY 200070 -3 afforded marked protection of CA1 neurons in approximately 40 -50% of estrogen-deprived female rats. WAY 200070 -3, administered at doses that afforded neuroprotection, did not elicit lordosis behavior, negative feedback inhibition of LH release, or a reduction in weight gain, providing independent validation that the drug does not crossreact with ER␣ in vivo. By contrast, the 10-mg/kg dose of PPT elicited all of these actions of E 2 that are known to be mediated, at least in part, by brain ER␣ receptors. We further show that global ischemia regulates ER expression in hippocampal neurons. There was a marked increase in ER␣ protein and a small, but not significant, decrease in ER␤ protein in CA1 at both 24 and 48 h after ischemia. Estrogen pretreatment mimicked the injury-induced increase in ER␣ protein expression, and the effects of ischemia and E 2 pretreatment were not additive. These data indicate that E 2 can act via ER␣ and ER␤ to protect CA1 pyramidal neurons from global ischemia-induced death and that both E 2 and global ischemia modulate ER␣ expression in the hippocampal CA1.
The finding that estrogen can act via either ER␣ or ER␤ to elicit protection of hippocampal neurons is of interest in that the cellular targets that mediate estrogen neuroprotection remain controversial. Studies involving transgenic mice with targeted deletion of either ER␣ or ER␤ indicate that ER␣ is critical to estrogen protection of cortical and striatal neurons in focal ischemia (21) . Interestingly, estrogen does not protect hippocampal neurons in that model, presumably because permanent occlusion of the middle cerebral artery is a catastrophic insult. There is one report that estrogen does not afford protection against focal ischemia-induced neuronal death in mice with targeted deletion of ER␣ (31), although ICI 182,780 administration increased infarct volume in this model (32). These investigators concluded that E 2 most likely exerts neuroprotection through the activation of ER␤, not ER␣ (31, 32). Interestingly, ER␣ has recently been implicated in the protective actions of estradiol in a model of ischemic liver injury (33).
There are also conflicting reports regarding the role of ER subtypes in neuroprotection after global ischemia. A recent pharmacological study showed that the ER␤-selective agonist diaryl propiolnitrile is more effective than PPT (2 mg/ kg) in protecting hippocampal neurons against global ischemia-induced death (22) . However, our data clearly show that a PPT dose of 2 mg/kg⅐d is not sufficient to fully activate ER␣-mediated responses to estrogen, such as lordosis behavior, LH suppression, and reduction of weight gain, in most female rats. Our finding that PPT at a higher dose (10 mg/kg) is as effective as the selective ER␤ agonist WAY 200070 -3 in affording neuroprotection suggests a role for both ER␣ and ER␤ in estrogen protection. There is also a preliminary report that PPT and unidentified ER␤-selective agonists are partially neuroprotective in gerbil CA1 after global ischemia (9) . These authors used in situ hybridization signals for neurogranin mRNA to quantify CA1 cell survival, and the duration and dose of agonist treatment were not always specified, so it is somewhat difficult to make direct comparisons between that report and our study. However, in agreement with our results using 2 mg/kg⅐d PPT, the latter authors detected no protection in ovariectomized gerbils when PPT was used at a dose of 3 mg/kg.
ER-selective agonist treatment and neuroprotection
In our experiments, ER␣-and ER␤-selective agonists produced a bimodal distribution of neuroprotection in rats subjected to global ischemia, with nearly complete survival of CA1 pyramidal neurons in 38 and 45% of animals, respectively, and less than 10% neuronal survival in the remainder of animals (Fig. 4) . This pattern of neuroprotection was in contrast to that of E 2 , which elicited approximately 50% neuronal survival in all animals (Fig. 2) . It is notable that, in our hands, a high dose of PPT (10 mg/kg) was necessary to prime lordosis, to suppress weight gain, and to suppress LH completely. The dose of PPT needed to produce biological responses when administered in vivo is in contrast to its high affinity in binding to ER␣, as assessed by radioligand assays in vitro (23) . Thus, it is possible that the ability of these drugs to promote neuronal survival in only a subset of ischemic animals reflects either their low intrinsic efficacy or individual differences in drug disposition and metabolism. However, the bimodal distribution in pyramidal neuron survival is unlikely to be entirely due to individual differences in penetration of drugs through the blood-brain-barrier or to their differential action at peripheral ERs, because neither serum LH levels nor body weight gain differed in rats that exhibited preservation vs. those that exhibited loss of CA1 pyramidal neurons. Others have reported that PPT at 2 mg/ kg⅐d prevented ovx-induced weight gain and maintained uterine weight and total and trabecular bone mineral density for as long as 6 wk in adult rats but that a higher dose (15 mg/kg⅐d) was required to prevent hot flashes (34). Thus, a relatively high dose of PPT may be required to elicit neural responses mediated by ER␣. We were unable to independently validate the ER␤ agonist dose used in our protection studies as physiologic, because there is currently no known behavioral or neuroendocrine response that is mediated exclusively via ER␤.
Although our findings suggest that either ER␣ or ER␤ can protect hippocampal neurons from ischemia-induced cell death, this conclusion must be tempered by the fact that we could not independently verify that WAY 200070 -3 actually activated ER␤ or that PPT failed to do so in the brain or in peripheral tissues. Likewise, we cannot rule out the possibility that both receptors must be activated to rescue CA1 pyramidal cells. Although our data suggest that WAY 200070 -3 did not activate brain ER␣, it is impossible to determine whether the high dose of PPT acted as an agonist at ER␤. We attempted to use ER knockout mice to clarify the role of ER subtypes in global ischemia; however, using the standard two-vessel occlusion model of global ischemia in mice, we were unable to reliably produce selective loss of CA1 pyramidal neurons in the wild-type strains upon which the ER knockouts were produced (data not shown). Therefore, the questions raised by our work may only be resolved by the development of highly selective ER␣ and ER␤ agonist and antagonist ligands that easily penetrate the blood-brainbarrier and mimic the biological activity of E 2 at brain ERs.
ER-selective agonists and physiologic responses mediated by brain ERs
The present study also shows that the ER␣ agonist PPT, but not the ER␤ agonist WAY 200070 -3, at doses used for protection, elicits lordosis behavior and negative feedback inhibition of LH release and attenuates weight gain. These studies establish an effective dose for PPT and validate the selectivity of WAY 200070 -3 in vivo. However, they do not rule out the possibility that PPT and WAY 200070 -3 action on nonneuronal target tissues may also contribute to the neuroprotection. Estrogen negative feedback and suppression of body weight gain involve estrogen action at peripheral (e.g. pituitary, adipose tissue) as well as neural sites. Likewise, we cannot rule out the possibility that the drugs acted on vascular tissues to improve postischemia reperfusion (e.g. see Ref. 5 ). This explanation is, however, less likely, in that physiological levels of E 2 protect neurons against global ischemia-induced cell death even when postischemic cerebral blood flow is strictly controlled (35).
Transgenic mice with targeted deletion of ER␣ or ER␤ have been used to delineate the differential actions of estrogen mediated by each receptor subtype. These studies implicate ER␣ in E 2 -dependent sexual receptivity (36 -38), negative feedback regulation of LH (24, 39) , and suppression of ovariectomy-induced increases in food intake and weight gain (40) . In contrast, female ER␤ null mutants exhibit normal lordosis responses (37) and normal serum LH levels (41) and are able to reproduce and lactate (42) . Our findings that PPT elicited the lordosis response, produced negative feedback inhibition of serum LH levels, and reduced the rate of weight gain in young, ovx female rats provide confirmation of a role for ER␣ in responses to estrogen that are mediated, at least in part, by brain receptors.
ER regulation by E 2 and after global ischemia
Our observation that ER␣ protein levels are significantly higher in CA1 when ovx rats receive E 2 replacement extends to the in vivo situation the recent finding that E 2 increases ER␣ protein levels in cultured hippocampal neurons (43) . There is now evidence that E 2 may be synthesized de novo in hippocampal neurons of both adult and developing rats (44, 45) and that it is important for maintaining hippocampal synaptic connections (46) . Therefore, E 2 may be an essential physiological regulator of hippocampal ER␣ expression and synaptic connectivity. Neuronal injury can also regulate expression of a number of genes, including those encoding ERs (9, 25, 26) . Our finding that global ischemia up-regulates ER␣ protein expression in the hippocampal CA1 is consistent with findings that focal ischemia up-regulates ER␣ mRNA expression in neocortex (25) . In contrast, global ischemia does not increase ER␣ expression in adult macaque monkeys, whereas it markedly increases glial ER␤ immunostaining in the CA1 of this species (47) . Our finding that neither global ischemia nor estrogen significantly alters ER␤ expression in CA1 thus stands in contrast to the reported actions of global ischemia in monkeys and to previous findings that focal ischemia causes a 50% decrease in ER␤ mRNA in the rat cerebral cortex, a response that was prevented by exogenous estrogen (25) . Hence, changes in receptor expression in response to neuronal injury are unlikely to account for the all-or-none effect of the ER-selective agonists in affording neuroprotection. Moreover, we cannot rule out the possibility that the recently described ER-X, whose levels also increase after ischemia (26) , or other molecular entities that bind E 2 and ICI 182,780 or that modulate the efficacy of ligand-induced transcriptional activation (48) also contribute to the neuroprotective actions of E 2 in vivo.
Summary
It is well established that estrogen affords neuroprotection in animal models of stroke and global ischemia. The present study shows that the neuroprotective actions of estrogen can be mediated by either ER␣ or ER␤ in a rat model of transient global ischemia. Our finding that the ER antagonist ICI 182,780 administered ICV abolishes protection by estrogen implicates brain ERs as the cellular mediators of estrogen neuroprotection and argues against a role for other, receptorindependent mechanisms. The ability of ICI 182,780 to abolish estrogen protection when given ICV only at 0 and 12 h after ischemia, despite the continued presence of estrogen, also demonstrates that E 2 action in the early postischemic period is critical. The up-regulation of ER␣ protein expression in CA1 observed at 24 and 48 h after ischemia, times at which histological evidence of cell death is not yet observed in ischemic rats, suggests that this may be a protective response by the injured brain. Delineation of the cellular targets that mediate neuroprotection by estrogen contributes to our understanding of how estrogen promotes neuronal survival and may help in the prevention and/or treatment of global ischemia arising during cardiac arrest.
